Abstract

Background: Anxiety disorders (ADs) are common with a high rate of medical comorbidities. Although the association between ADs and the overall cancer risk remains controversial, patients with ADs were found to be more likely to develop specific cancer types. Herein, we estimated the risk of developing urological cancers among patients with ADs in a 5-year follow-up period using a population-based database. Methods: Two study cohorts were identified from the Taiwan Longitudinal Health Insurance Database 2005: patients with ADs, and comparison subjects selected by one-to-one matching for sex, age, and the year of recruitment. Follow-up was undertaken to determine whether sampled patients and comparison subjects had developed urological cancers in the subsequent 5 years. Results: We found that urological cancers occurred among 0.54% of patients with ADs and 0.13% of comparison subjects. After adjusting for sociodemographic characteristics, medical comorbidities, and alcohol and tobacco use disorder, the stratified Cox proportional hazard regression suggested that patients with ADs were more likely to develop urological cancers relative to comparison subjects (adjusted hazard ratio, 3.67; 95% confidence interval, 2.85 ∼ 4.72). The adjusted HR for males with ADs was 3.82 (95% CI: 2.79 ∼ 5.23) in comparison to males without ADs. In addition, the adjusted HR for females with ADs was 3.47 (95% CI: 2.26 ∼ 5.31) than those females without ADs. Conclusions: We concluded that during the 5-year follow-up period, there was a significantly increased risk of urological cancers among patients with ADs.

Original languageEnglish
Article number67
JournalBMC Urology
Volume16
Issue number1
DOIs
Publication statusPublished - Nov 16 2016

Fingerprint

Urologic Neoplasms
Anxiety Disorders
Cohort Studies
Retrospective Studies
Comorbidity
Databases
Tobacco Use Disorder
Health Insurance
Taiwan
Neoplasms

Keywords

  • Anxiety disorder
  • Bladder cancer
  • Epidemiology
  • Urological cancer

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Increased risk for urological cancer associated with anxiety disorder : A retrospective cohort study. / Chen, Yung Chan; Kao, Li Ting; Lin, Herng-Ching; Lee, Hsin-Chien; Huang, Chung-Chien; Chung, Shiu Dong.

In: BMC Urology, Vol. 16, No. 1, 67, 16.11.2016.

Research output: Contribution to journalArticle

@article{f3e9b2ed0ea947a3a40153e0be5fdb78,
title = "Increased risk for urological cancer associated with anxiety disorder: A retrospective cohort study",
abstract = "Background: Anxiety disorders (ADs) are common with a high rate of medical comorbidities. Although the association between ADs and the overall cancer risk remains controversial, patients with ADs were found to be more likely to develop specific cancer types. Herein, we estimated the risk of developing urological cancers among patients with ADs in a 5-year follow-up period using a population-based database. Methods: Two study cohorts were identified from the Taiwan Longitudinal Health Insurance Database 2005: patients with ADs, and comparison subjects selected by one-to-one matching for sex, age, and the year of recruitment. Follow-up was undertaken to determine whether sampled patients and comparison subjects had developed urological cancers in the subsequent 5 years. Results: We found that urological cancers occurred among 0.54{\%} of patients with ADs and 0.13{\%} of comparison subjects. After adjusting for sociodemographic characteristics, medical comorbidities, and alcohol and tobacco use disorder, the stratified Cox proportional hazard regression suggested that patients with ADs were more likely to develop urological cancers relative to comparison subjects (adjusted hazard ratio, 3.67; 95{\%} confidence interval, 2.85 ∼ 4.72). The adjusted HR for males with ADs was 3.82 (95{\%} CI: 2.79 ∼ 5.23) in comparison to males without ADs. In addition, the adjusted HR for females with ADs was 3.47 (95{\%} CI: 2.26 ∼ 5.31) than those females without ADs. Conclusions: We concluded that during the 5-year follow-up period, there was a significantly increased risk of urological cancers among patients with ADs.",
keywords = "Anxiety disorder, Bladder cancer, Epidemiology, Urological cancer",
author = "Chen, {Yung Chan} and Kao, {Li Ting} and Herng-Ching Lin and Hsin-Chien Lee and Chung-Chien Huang and Chung, {Shiu Dong}",
year = "2016",
month = "11",
day = "16",
doi = "10.1186/s12894-016-0187-x",
language = "English",
volume = "16",
journal = "BMC Urology",
issn = "1471-2490",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Increased risk for urological cancer associated with anxiety disorder

T2 - A retrospective cohort study

AU - Chen, Yung Chan

AU - Kao, Li Ting

AU - Lin, Herng-Ching

AU - Lee, Hsin-Chien

AU - Huang, Chung-Chien

AU - Chung, Shiu Dong

PY - 2016/11/16

Y1 - 2016/11/16

N2 - Background: Anxiety disorders (ADs) are common with a high rate of medical comorbidities. Although the association between ADs and the overall cancer risk remains controversial, patients with ADs were found to be more likely to develop specific cancer types. Herein, we estimated the risk of developing urological cancers among patients with ADs in a 5-year follow-up period using a population-based database. Methods: Two study cohorts were identified from the Taiwan Longitudinal Health Insurance Database 2005: patients with ADs, and comparison subjects selected by one-to-one matching for sex, age, and the year of recruitment. Follow-up was undertaken to determine whether sampled patients and comparison subjects had developed urological cancers in the subsequent 5 years. Results: We found that urological cancers occurred among 0.54% of patients with ADs and 0.13% of comparison subjects. After adjusting for sociodemographic characteristics, medical comorbidities, and alcohol and tobacco use disorder, the stratified Cox proportional hazard regression suggested that patients with ADs were more likely to develop urological cancers relative to comparison subjects (adjusted hazard ratio, 3.67; 95% confidence interval, 2.85 ∼ 4.72). The adjusted HR for males with ADs was 3.82 (95% CI: 2.79 ∼ 5.23) in comparison to males without ADs. In addition, the adjusted HR for females with ADs was 3.47 (95% CI: 2.26 ∼ 5.31) than those females without ADs. Conclusions: We concluded that during the 5-year follow-up period, there was a significantly increased risk of urological cancers among patients with ADs.

AB - Background: Anxiety disorders (ADs) are common with a high rate of medical comorbidities. Although the association between ADs and the overall cancer risk remains controversial, patients with ADs were found to be more likely to develop specific cancer types. Herein, we estimated the risk of developing urological cancers among patients with ADs in a 5-year follow-up period using a population-based database. Methods: Two study cohorts were identified from the Taiwan Longitudinal Health Insurance Database 2005: patients with ADs, and comparison subjects selected by one-to-one matching for sex, age, and the year of recruitment. Follow-up was undertaken to determine whether sampled patients and comparison subjects had developed urological cancers in the subsequent 5 years. Results: We found that urological cancers occurred among 0.54% of patients with ADs and 0.13% of comparison subjects. After adjusting for sociodemographic characteristics, medical comorbidities, and alcohol and tobacco use disorder, the stratified Cox proportional hazard regression suggested that patients with ADs were more likely to develop urological cancers relative to comparison subjects (adjusted hazard ratio, 3.67; 95% confidence interval, 2.85 ∼ 4.72). The adjusted HR for males with ADs was 3.82 (95% CI: 2.79 ∼ 5.23) in comparison to males without ADs. In addition, the adjusted HR for females with ADs was 3.47 (95% CI: 2.26 ∼ 5.31) than those females without ADs. Conclusions: We concluded that during the 5-year follow-up period, there was a significantly increased risk of urological cancers among patients with ADs.

KW - Anxiety disorder

KW - Bladder cancer

KW - Epidemiology

KW - Urological cancer

UR - http://www.scopus.com/inward/record.url?scp=84995520607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995520607&partnerID=8YFLogxK

U2 - 10.1186/s12894-016-0187-x

DO - 10.1186/s12894-016-0187-x

M3 - Article

C2 - 27852299

AN - SCOPUS:84995520607

VL - 16

JO - BMC Urology

JF - BMC Urology

SN - 1471-2490

IS - 1

M1 - 67

ER -